Medigene AG Medigene AG

Medigene AG

MDG1

Peringkat dalam Saham #35331
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Universitรฉ de Montrรฉal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Harga Saham
$0.14942078
Terakhir disinkronkan: 2025-05-15
Kapitalisasi Pasar
$3.86M
Perubahan (1 hari)
0.10%
Perubahan (1 tahun)
39.97%
Negara
DE
Perdagangan Medigene AG (MDG1)

Kategori

Healthcare
Riwayat hasil dividen untuk Medigene AG (MDG1)
Hasil dividen (TTM) dari Medigene AG (simbol saham: MDG1) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Medigene AG (MDG1) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
Perusahaan Hasil Dividen Negara
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL